Corgenix Medical Corporation has been expanding the availability of its AspirinWorks test kit both domestically and overseas since it received FDA clearance in 2007. However the biggest announcement from the company came yesterday when the company announced the test would be available to physicians and laboratories through Quest Diagnostics, which is the leading provider of diagnostic tests and testing supplies in the country.
AspirinWorks is a revolutionary test that only requires a small urine sample as opposed to comparable tests which require freshly drawn blood. The test determines the effect of aspirin on platelets by measuring the level of thromboxane production. The higher the levels of thromboxane, the stickier the blood platelets, and the less impact the aspirin is having. This information allows physicians to individualize a patient’s therapy.
For the fiscal year ended June 30, 2007 Corgenix Medical had net sales of $7.36 million internationally. This is an increase of over 11% from the previous year when the company recorded sales of $6.63 million. Corgenix continues to research and develop additional tests with hopes for increased sales in the future. The company spent over $812,000, or 11% of their sales on research and development in 2007.
Corgenix is a Denver, Colorado based company, but has its international headquarters in Cambridge, England. The company is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. Corgenix currently sells 52 diagnostic products and believes their vision and commitment will place the company at the forefront of the health management field.
Let us hear your thoughts below: